ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vosaroxin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

28 träffar

Bibliografisk träff 2019-12-01

Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.

Jasek-Gajda E, Jurkowska H, Jasińska M, Litwin JA, Lis GJ.

Apoptosis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s10495-019-01564-6

Bibliografisk träff 2019-06-01

Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.

Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Sun L, Ge Y.

Target Oncol · research support, non-u.s. gov't; journal article · DOI 10.1007/s11523-019-00638-4

Bibliografisk träff 2018-11-01

TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.

Jasek-Gajda E, Gajda M, Jasińska M, Litwin JA, Lis GJ.

Anticancer Res · journal article · DOI 10.21873/anticanres.12967

Bibliografisk träff 2018-05-24

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica · letter; clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial · DOI 10.3324/haematol.2018.191361

Bibliografisk träff 2018-05-22

Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.

Zhao XL, Yu CZ.

Chem Biol Interact · journal article · DOI 10.1016/j.cbi.2018.05.011

Bibliografisk träff 2017-08-07

Therapies for acute myeloid leukemia: vosaroxin.

Sayar H, Bashardoust P.

Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s121477

Bibliografisk träff 2017-07-20

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F.

Haematologica · research-article; journal article · DOI 10.3324/haematol.2017.168732

Bibliografisk träff 2017-05-22

The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.

Paubelle E, Zylbersztejn F, Thomas X.

Expert Opin Drug Discov · review; journal article · DOI 10.1080/17460441.2017.1331215

Bibliografisk träff 2017-05-01

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

Gravina GL, Mancini A, Mattei C, Vitale F, Marampon F, Colapietro A, Rossi G, Ventura L, Vetuschi A, Di Cesare E, Fox JA, Festuccia C.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.16168

Bibliografisk träff 2017-04-21

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.

Sedov V, Stuart RK.

Ther Adv Hematol · review-article; review; journal article · DOI 10.1177/2040620717703012

Bibliografisk träff 2017-01-31

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

Nijenhuis CM, Lucas L, Rosing H, Huitema ADR, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JHM, Beijnen JH.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-017-0428-1

Bibliografisk träff 2016-09-12

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Benton CB, Ravandi F.

Future Oncol · review-article; review; journal article · DOI 10.2217/fon-2016-0300

Bibliografisk träff 2016-09-01

Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.

Jamieson GC, Fox JA, Poi M, Strickland SA.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-016-0614-z

Bibliografisk träff 2016-05-24

The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.

Short NJ, Ravandi F.

Expert Rev Hematol · review; journal article · DOI 10.1080/17474086.2016.1187063

Bibliografisk träff 2016-05-13

Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry.

Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci · validation study; journal article · DOI 10.1016/j.jchromb.2016.05.016

Bibliografisk träff 2015-07-30

Vosaroxin in acute myeloid leukaemia.

Bornhäuser M.

Lancet Oncol · comment; journal article · DOI 10.1016/s1470-2045(15)00165-5

Bibliografisk träff 2015-05-10

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.

Hotinski AK, Lewis ID, Ross DM.

Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.2015.1044437

Bibliografisk träff 2015-03-24

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood · comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1182/blood-2014-10-608117

Bibliografisk träff 2015-02-01

Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin.

Mjos KD, Cawthray JF, Jamieson G, Fox JA, Orvig C.

Dalton Trans · research support, non-u.s. gov't; journal article · DOI 10.1039/c4dt02934h

Bibliografisk träff 2014-11-17

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1111/bjh.13214

Bibliografisk träff 2014-11-07

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.3324/haematol.2014.114769

Bibliografisk träff 2013-05-20

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

Freeman C, Keane N, Swords R, Giles F.

Expert Opin Pharmacother · journal article · DOI 10.1517/14656566.2013.799138

Bibliografisk träff 2012-06-23

Vosaroxin : a novel antineoplastic quinolone.

Abbas JA, Stuart RK.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.699038

Bibliografisk träff 2012-02-27

Radiosensitization by the novel DNA intercalating agent vosaroxin.

Gordon IK, Graves C, Kil WJ, Kramp T, Tofilon P, Camphausen K.

Radiat Oncol · research support, n.i.h., intramural; research-article; journal article · DOI 10.1186/1748-717x-7-26

Bibliografisk träff 2010-04-15

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA.

PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0010186

Bibliografisk träff 2008-12-12

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.

Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.108.023432

Bibliografisk träff 2008-10-19

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-008-0850-3

Bibliografisk träff 2004-04-01

Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2.

Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K.

J Med Chem · journal article · DOI 10.1021/jm0304966